자궁경부암 백신접종의 최신지견 = Update of human papillomavirus vaccination

다국어 초록 (Multilingual Abstract)

Infection with one of 15 types of high-risk human papillomavirus (HPV) is the cause of cervical cancer. Worldwide, 70% of cervical cancer is caused by either HPV type 16 or 18. The current HPV vaccine is composed of virus-like particles (VLPs) of the L1 capsid protein as well as adjuvant. Quadrivalent HPV vaccine contains L1 VLPs from HPV types 6, 11, 16, and 18, and the bivalent vaccine contains HPV 16 and 18 L1 VLPs. HPV vaccines have demonstrated almost 100% efficacy in preventing HPV 16- or 18- associated cervical intraepithelial neoplasia grade 3 or worse (CIN3+) in large-scale randomized studies. The HPV vaccine was confirmed to be safe by the WHO Global Advisory Committee for Vaccine Safety after reviewing information from clinical trials and post-marketing surveillance of two HPV vaccines.

Local injection site reactions were the most commonly observed side effect, and these resolved spontaneously. A three-dose schedule is recommended prior to sexual contact and potential exposure to HPV, but a two-dose schedule is also recommended for adolescent girls aged 9 to 13 years. Recently, cervical cancer screening and HPV vaccination to prevent cervical cancer and HPV-related disease have become major public health issues. The effects of HPV vaccination, such as a rapid decrease in HPV prevalence, genital warts, and cervical precancerous lesions, have been observed in several countries in which HPV vaccination coverage is very high. At this point, cost-effectiveness analysis should be performed in Korea with the view to include HPV vaccination in the national immunization program to increase the coverage of HPV vaccination. In the future, we can eradicate cervical cancer through the universal HPV prophylactic vaccine and therapeutic HPV vaccine, together with cervical cancer screening.

참고문헌 (Reference)

1 Clifford GM, "Worldwide distribution of hu-man papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys : a pooled analysis" 366 : 991-998, 2005

2 Joura E, "VS03-001 Study Team. Efficacy and immunogenicity of a novel 9-valent HPV L1 virus-like particle vaccine in 16- to 26-year-old women" 102-, 2013

3 Angelo MG, "Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine : more than 4 years of experience" 23 : 456-465, 2014

4 Goss MA, "No adverse signals observed after exposure to human papillomavirus type 6/11/16/18 vaccine during pregnancy : 6-year pregnancy registry data" 123 (123): 93-, 2014

5 Canfell K, "Modeling preventative strategies against human papillomavirus-related disease in developed countries" 30 (30): 157-167, 2012

6 Ministry of Health and Welfare, "Korea central cancer registry" Ministry of Health and Welfare 2014

7 Gertig DM, "Impact of a population-based HPV vaccination program on cervical abnormalities : a data linkage study" 11 : 227-, 2013

8 Dobson SR, "Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women : a randomized clinical trial" 309 : 1793-1802, 2013

9 Romanowski B, "Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination : results from a randomized study" 10 : 1155-1165, 2014

10 "Human papillomavirus vaccines : WHO position paper, October 2014" 89 : 465-491, 2014

11 Kemp TJ, "HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection" 29 : 2011-2014, 2011

12 Ali H, "Genital warts in young Australians five years into national human papillomavirus vaccination programme : national surveillance data" 346 : 2032-, 2013

13 FUTURE I/II Study Group, "Four year efficacy of prophylactic human papilloma-virus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts : ran-domised controlled trial" 341 : 3493-, 2010

14 Garland SM, "Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vac-cine against human papillomavirus to prevent anogenital diseases" 356 : 1928-1943, 2007

15 Tabrizi SN, "Fall in human papillomavirus prevalence following a national vaccination program" 206 : 1645-1651, 2012

16 Paavonen J, "Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA) : final analysis of a double-blind, randomised study in young women" 374 : 301-314, 2009

17 De Villiers EM, "Cross-roads in the classification of papilloma-viruses" 445 : 2-10, 2013

18 Malagon T, "Cross-protective efficacy of two human papillo-mavirus vaccines : a systematic review and meta-analysis" 12 : 781-789, 2012

19 Einstein MH, "Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus(HPV)cervical cancer vaccines in healthy women aged 18-45 years" 5 : 705-719, 2009